Opendata, web and dolomites

FuseX

Novel device for simple and effective prevention of post-surgical adhesion build up.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FuseX project word cloud

Explore the words cloud of the FuseX project. It provides you a very rough idea of what is the project "FuseX" about.

natural    hopes    mix    antibiotics    translates    rapid    expenses    stress    anti    trials    procedure    safety    plasma    mixture    coagulation    readmitted    eio    abdominal    initially    whilst    depending    chain    hospitals    found    yair    material    delivers    preliminary    infertility    blood    difficulties    multitude    35    strategy    function    surgery    clinics    undergo    adhesion    healthcare    eliminate    surgical    fusex    potentially    supply    consequence    lithuania    concentrated    adverse    initiate    12    donor    saved    innovation    revolutionary    laparoscopic    adhesions    chronic    biomedical    question    dr    untreated    killers    initial    ceo    pilpel    size    pain    operations    complications    invasive    integrate    drafted    solidify    market    grow    device    solution    pelvic    unnecessary    spain    demonstrated    trauma    additional    inflammatories    schools    solutions    patients    twice    wound    post    severity    barriers    commercialization    plan    efficiency    repeat    90    putting    efficacy   

Project "FuseX" data sheet

The following table provides information about the project.

Coordinator
EIO BIOMEDICAL LTD 

Organization address
address: 13 WADI EL HAJ
city: NAZARETH
postcode: 17111
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://www.eiobio.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EIO BIOMEDICAL LTD IL (NAZARETH) coordinator 50˙000.00

Map

 Project objective

Surgical adhesions are a consequence of abdominal trauma during surgery. Although there are a multitude of available barriers on the market today, the efficacy of these solutions is still in question and can lead to adverse side effects. If untreated, these surgical adhesions can solidify and grow, potentially leading to infertility, chronic pain, and difficulties in repeat operations. To address adhesions, patients must undergo additional abdominal surgery, putting unnecessary stress on existing healthcare systems. On average, 35% of patients who undergo open abdominal or pelvic surgery are readmitted twice in the following 10 years due to complications. EIO Biomedical has developed a revolutionary anti-adhesion system in order to eliminate initial formation of surgical adhesions. The FuseX system, delivers a mixture of donor blood plasma with a concentrated mix of natural coagulation factors found in the blood. This results in less post-surgical adhesions, and related complications, and translates to an estimated 6-12 B€ in saved expenses per year. Preliminary testing of the material demonstrated a 60-90% reduction of adhesions, depending on the severity, whilst the non-invasive laparoscopic application also reduced open wound size and extent of trauma. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project, EIO Biomedical is set to initiate safety and efficiency trials in Lithuania and Spain, where they will initially market their product. After initial testing, device function and efficiency will be further improved to enable a more rapid procedure for scale up to commercialization. Post-commercialization, CEO Dr. Yair Pilpel hopes to integrate anti-inflammatories, pain killers, and antibiotics, into the solution for widespread use in hospitals, clinics, and potentially schools.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUSEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FUSEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More